News

Good prospects for the future

Read about the progress we have made and the milestones we have reached, about our growth and our experts, about our commitment and our communication, in short: everything that concerns us.
04/2019
PRESS:

New hope for pharmacoresistant focal epilepsy: EASEE® Neurostimulation – first ever implantation in Freiburg

Globally, epilepsy is one of the most common chronic neurological conditions and greatly limits the lives of those affected. Approximately every third patient is refractory to […]
10/2018
PRESS:

Go-ahead for the first human implant

EASEE®, the innovative brain stimulation system developed by Precisis AG, has successfully completed the preclinical trial phase. For the first time, patients suffering from focal epilepsy […]
10/2018
PRESS:

Precisis AG receives BMBF funding for “Individualised medical technology”

Precisis AG, together with the Department of Microsystems Engineering at the Albert-Ludwigs University Freiburg and the Epilepsy Centre at the Freiburg University Clinic, has initiated a […]
09/2018
SCIENCE:

Cognition and epilepsy

In a special publication of the national FRANKFURTER ALLGEMEINE ZEITUNG, Prof. Dr. Christoph Helmstaedter, epileptologist and Director of the Neuropsychology Department of the Epileptology Clinic at […]
07/2017
GROWTH:

Precisis AG concludes capital increase Q2/2017

Precisis AG has closed its next financing round in Q2/2017. Apart from the original group of shareholders that has remained unchanged for many years, three further […]
07/2017
SUCCESS:

First tests confirm good tolerability

The first short-term trial EASEE IB with outpatients at three selected epilepsy centres nationwide showed a good function and tolerability of the EASEE® stimulation. A total […]